Loading...

FibroBiologics, Inc. Common Stock

FBLG•NASDAQ
HealthcareBiotechnology
$0.83
$-0.01(-1.01%)

FibroBiologics, Inc. Common Stock (FBLG) Stock Overview

Explore FibroBiologics, Inc. Common Stock’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for FBLGStats details for FBLG are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$9.00
Average$9.00
High$9.00

Company Profile

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

CEO

Mr. Peter O'Heeron

Employees

13

Headquarters

455 East Medical Center Boulevard, Houston, DE

Founded

2024

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.